Glucagon-like peptide (GLP-1), a major physiological incretin, plays numerous important roles in modulating blood glucose homeostasis and has been proposed for the treatment of type 2 diabetes. The major obstacles for using native GLP-1 as a therapeutic agent are that it must be delivered by a parenteral route and has a short half-life. In an attempt to develop a strategy to prolong the physiological t 1/2 and enhance the potency of GLP-1, a fusion protein consisting of active human GLP-1 and mouse IgG 1 heavy chain constant regions (GLP-1/Fc) was generated. A plasmid encoding an IgK leader peptide-driven secretable fusion protein of the active GLP-1 and IgG 1 -Fc was constructed for mammalian expression. This plasmid allows for expression of bivalent GLP-1 peptide ligands as a result of IgG-Fc homodimerization. In vitro studies employing purified GLP-1/ Fc indicate that the fusion protein is functional and elevates cAMP levels in insulin-secreting INS-1 cells. In addition, it stimulates insulin secretion in a glucose concentrationdependent manner. Intramuscular gene transfer of the plasmid in db/db mice demonstrated that expression of the GLP-1/Fc peptide normalizes glucose tolerance by enhancing insulin secretion and suppressing glucagon release. This strategy of using a bivalent GLP-1/Fc fusion protein as a therapeutic agent is a novel approach for the treatment of diabetes.
Introduction
Glucagon-like peptide-1 (7-36)-amide (GLP-1), a 30-amino-acid peptide hormone secreted from intestinal L-cells in response to nutrient ingestion, promotes nutrient absorption via regulation of islet hormone secretion.
1 GLP-1 binds to the GLP-1 receptor (GLP-1R) which mediate its effects via the cyclic AMP second messenger pathway. 1 GLP-1R is a G-protein coupled receptor (GPCR) found in several target tissues including b-cells in pancreatic islets, 2 brain, kidney, heart and the gastrointestinal tract. 3 Several signaling molecules including phoshatidylinositiol-3-kinase (PI3K), 4 MAPK, 5 Akt, 6, 7 and PKCz 8 mediate GLP-1 signals to intracellular effectors. In normal and diabetic human subjects infusion of GLP-1 leads to stimulation of insulin secretion 9, 10 and inhibition of glucagon secretion, 11, 12 thereby indirectly modulating peripheral glucose uptake and control of hepatic glucose production. 13 Also, GLP-1 improves peripheral insulin resistance [14] [15] [16] and in turn renders pancreatic b-cells glucose competent. 17 Importantly, GLP-1 enhances b-cell mass via inhibition of b-cell apoptosis and stimulation of b-cell proliferation in rodents 6, 13, 18, 19 and in humans. 20 As a result of these important biological features, GLP-1 has been evaluated for use in the treatment of T2D. In normal, obese and diabetic human subjects, short-term infusion of GLP-1 also mediates anorectic effects including enhanced satiety, reduced energy consumption, reduced appetite and diminished energy. 21 Despite its desirable antidiabetic actions, its therapeutic potential is limited by its short circulating t 1/2 (o2 min) that results mainly from rapid enzymatic inactivation by dipeptidyl peptidase, DPP-IV, 22, 23 and/ or renal clearance. 24 From this perspective, significant efforts have been made to develop long-acting degradation-resistant GLP-1 mimetic peptides. Human GLP-1 analogs with amino-acid substitutions 25, 26 and/or N-terminal modifications including fatty acylated 27 and N-acetylated 28 exhibit significantly prolonged circulating t 1/2 , and potently reduce glycemic excursion in diabetic subjects. 27 Exendin-4 (Ex-4), a lizard salivary gland peptide, is a potent GLP-1R agonist that also has therapeutic potential because of its high sequence homology to mammalian GLP-1 and resistance to enzymatic degradation. 29 In addition, several fusion proteins conjugating GLP-1 to other peptides have been designed and evaluated. Albumin protein-conjugated GLP-1 molecules (Albugon and CJC-1131) display many anti-diabetic and other beneficial features of GLP-1 along with a substantially prolonged half-life. 28, 30 Although DPP-IV-resistant GLP-1R agonists appear to be promising therapeutic drug candidates for the treatment of diabetes, these peptides require once-or twice-daily injections and/or combination therapies with oral diabetic medications. The substantially prolonged half-life of GLP-1-albumin fusion proteins is likely due to reduced renal clearance as a result of its larger size. However, in vitro studies have shown that the fusion protein displays a lower potency than Ex-4. 28, 30 These shortcomings continue to foster complementary efforts to generate more potent longer-acting agents with sustained efficacy in vivo.
We developed a strategy to prolong the physiological t 1/2 and enhance the potency of GLP-1 by generating a fusion protein consisting of active human GLP-1 and mouse IgG 1 heavy chain constant regions (GLP-1/Fc). A plasmid encoding a secretable fusion protein of the active GLP-1 and IgG 1 -Fc was constructed for mammalian expression of bivalent GLP-1 peptide ligands. The potentially increased circulating t 1/2 of such IgG-'carrier' drugs has been shown to be an effective treatment option by weekly injections. [31] [32] [33] Also, given that most of the GPCRs are pre-formed in the cell membrane in the form of dimers and oligomers, dimeric ligands are expected to possess substantially increased affinity. 34, 35 In order to study the biological properties and effectiveness of the recombinant human chimeric GLP-1 fusion protein, GLP-1/Fc, we have examined the peptidergic actions of GLP-1-Fc using a combination of in vitro cell line studies and by intramuscular gene transfer and expression in a type 2 diabetic mouse model in vivo. This gene therapy approach appears to be effective in lowering blood glucose levels in a murine model of severe T2D, and the therapeutic effect is long lasting.
Materials and methods

Plasmid construction
Full length GLP-1 and mouse IgG-Fc cDNAs were amplified from GLP-1/PCR2.1 (kind gift from Dr X Huang) and IgG/VRnew plasmids, respectively, using gene specific primers and an overlap PCR strategy as outlined in the schematic representation (Figure 1a ). For the first overlap PCR, 5 0 -CCGGATATCGCCACCATG GAGACAGACACACTCCTGCTATGGGTACTGCTGCT CTGGGTTCCAGGTTCCACTGGTGACCA-3 0 and 5 0 -TG CTGAAGGGACCTTTACCAGTG-3 0 were used. The PCR products were used in a second overlap PCR to produce a contingent GLP-1/IgG-Fc cDNA. The amplification products were sub-cloned into the BamHI and EcoRV sites of the VRnew vector, constructed from VR1255. 36 For the control vector that encodes IgG-Fc, IgG cDNA alone was amplified by PCR using 5 0 -CCGGATATCGC CACCATGGAGACAGACACACTCCTGCTATGGGTAC TGCTGCTCTGGGTTCCAGGTTCCACTGGTGACCCCA GCGAGACCGTCACC-3 0 and 5 0 -CGCGGATCCCTATC ATTTACCAGGAGAGTGGGAGAGG-3 0 and cloned into the BamHI and EcoRV sites of the VRnew vector. The vector contains a CMV immediate-early enhancer-promoter, a single eukaryotic transcription unit, and minimal rabbit b-globin polyadenylation and transcription termination sequences. 36 The VRnew vector is a derivative of the VR1255 vector, 36 which has been modified by deleting the luciferase reporter gene and adding enzyme restriction sites. To permit secretion, the IgK signal peptide sequence was introduced 5 0 to the GLP-1 or Ex-4 sequence by PCR. To express GLP-1/IgG-Fc fusion proteins in bacteria, the fusion cDNA sequences were amplified by PCR from the VRnew plasmids and subcloned into the pET-28a (Novagen, EMD Bioscience, San Diego, CA, USA) vector.
Expression of IgG fusion proteins
For mammalian expression, GLP-1-IgG-Fc/VRnew or IgG-Fc/VRnew plasmid was transfected into COS-7 cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to manufacturer's instructions. Briefly, cells grown in six-well plates (2.5 Â 10 5 cells/well) were incubated with 4 mg of DNA using 10 ml of Lipofectamine in serum-and antibiotic-free DMEM (Invitrogen). At 6 h after transfection, the transfection medium was replaced with complete DMEM containing 10% FBS and 1% penicillin/streptomycin. The medium and the cells were separately harvested 48 h after transfection. For largescale expression of GLP-1/Fc fusion proteins, COS-7 cells grown in 150 mm dishes were transfected with 80 mg of relevant plasmid using cationic transfection reagent, Poly(ethyleneimine) (PEI, 25 kDa). Briefly, DNA and PEI were separately diluted in 150 mM NaCl, mixed and incubated for 20 min. The DNA/PEI complexes were added to cells and incubated for 6 h in serum-and antibiotic-free medium. The medium was replaced with DMEM, 10% FBS and 1% P/S. This method results B85% transfection efficiency (data not shown).
GLP-1/Fc and IgG-only peptides were expressed in Rosetta gami 2 bacteria (Novagen, EMD biosciences, San Diego, CA, USA). After cells were transformed with GLP-1/IgG-Fc/pET28a or IgG-Fc/pET28a vectors (Novagen), several individual colonies were selected and screened for optimal expression of the fusion proteins. For protein expression, a single colony of bacteria was used to inoculate 50 ml of 2X YT (with kanamycin) medium and grown overnight at 371C. The culture was then diluted into fresh medium (1:50) and grown to OD 600 0.6. The expression was induced with 1 mM IPTG (EMD Biosciences) for 3 h. The bacteria were harvested and the pellet was stored at À801C until further processing.
Purification of GLP-1/IgG-Fc fusion proteins
For mini-purification, the medium collected from the transfected cells (typically 2.5 ml from each well of a six-well plate) was added to 70 ml (packed volume) of pre-washed Protein G Sepharose 4 Fast flow resin (Amersham-Pharmacia, Piscataway, NJ, USA) in buffer containing 100 mM Tris pH 8.0 and 150 mM NaCl. After overnight incubation at 41C and extensive washing with the Tris buffer, proteins were eluted directly from the resin by addition of 30 ml of SDS sample buffer.
The midi-scale purification was used to acquire larger quantities of the fusion proteins. Briefly, 50 ml of DMEM medium collected 48 h post-transfection was incubated with Protein G Sepharose (1 ml packed volume, Amersham-Pharmacia). The incubations were performed overnight at 41C in the presence of 1% Triton X-100. After extensive washing with PBS containing 0.1% Triton X-100, and a final wash with 150 mM NaCl, proteins were eluted from the resin using 1 ml of 0.1 M glycine (pH 2.7). The elutions were immediately neutralized with Tris pH 9.0 buffer and the purified proteins were desalted using PD-10 columns (Amersham-Pharmacia) and eluted in PBS.
Similar approaches were used for the purification of the fusion proteins from bacteria. Extraction of solublized bacterial proteins was as the following (all: the bacterial pellets were resuspended in ice-cold PBS containing a protease inhibitor cocktail (Sigma, St Louis, MO, USA) and the cells were lysed by sonication. Proteins were solubilized using 1% Triton X-100 in PBS for 30 min. The centrifugation-clarified (12 000 g, 10 min) supernatant containing the fusion proteins was collected. SDS PAGE and/or Western blotting. Mini-scaled purified fusion proteins (30 ml in SDS sample buffer) were resolved by 10% SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was probed with anti-mouse antibody recognizing the mouse IgG-Fc (1:5000, Amersham-Pharmacia) and visualized by ECL (Amersham-Pharmacia). Midi-scale purified fusion proteins (30 ml) were separated by 10% SDS-PAGE and visualized by Coomassie Blue staining.
In vivo expression of GLP-1/FC in mice
Diabetic db/db mice (Jackson Laboratories, Bar Harbor, ME, USA) were subjected to DNA injection/electroporation as previously described with minor modifications. 37, 38 Briefly, anesthetized mice were injected in both tibialis anterior muscles with 25 mg of either GLP-1/ IgG-Fc/VRnew or IgG-Fc/VRnew plasmids in PBS using a 27-gauge needle fitted with a plastic collar limiting muscle penetration to approximately 1 mm. The muscles were electroporated using electrodes fitted to a pair of calipers with eight 200 V/cm square wave pulses (1 s apart). Blood was taken from the saphenous vein under fasting conditions at 4, 6 and 32 weeks after the DNA injection. The fasting blood glucose levels were measured using One Touch Basic glucose meter (Lifescan Canada, Burnaby, British Columbia, Canada), and the GLP-1, insulin and glucagon levels were measured as described below.
GLP-1 secretion assay
Using the total (all forms) GLP-1 RIA kit (Linco), GLP-1 levels were measured from the media (150 ml) collected from COS-7 cells transiently transfected with GLP-1/Fc or from the lysates of bacteria expressing the fusion proteins. For in vivo detection, GLP-1 levels in serum from db/db mice were determined using an active GLP-1 ELISA kit (Linco).
Insulin and glucagon secretion assay
INS-1 cells were plated in 24-well plates at a density of 2.5 Â 10 5 cells/well in RPMI 1640 medium containing 10% FBS. The following day, the medium was replaced with fresh KRB buffer devoid of glucose for 2 Â 60 min. The cells were then treated with 0 or 5 mM glucose and various concentrations of purified GLP-1/Fc fusion proteins in KRB buffer for 2 h. The insulin levels in conditioned KRB buffer (25 ml) were measured using a rat insulin RIA kit (Linco, St Charles, MO, USA). Plasma samples from db/db mice fasted for 16 h were analyzed for insulin and glucagon levels using a rat insulin RIA kit or rat glucagon RIA kit (Linco), according to the manufacturers' instructions.
Measurement of cAMP
INS-1 cells were plated at 62 500 cells/well in 24-well plates. The cells were serum starved in serum free RPMI
(SF-RPMI) containing 100 mM IBMX for 5 h before treatment the following day. The cells were subsequently incubated with purified Fc-fusion peptides (120 nM) or Ex-4 (100 nM) for 10 min in 450 ml of SF-RPMI medium. The assay was terminated by the addition of 1 ml of icecold ethanol. The extracts were incubated at À201C for 3 h to overnight following which 200 ml of the extracts were aliquoted and lyophilized. The lyophilized extracts were resuspended in 50 ml of sodium acetate assay buffer and used in cAMP RIAs (Biomedical Technologies, Stoughton, MA, USA).
Results
Plasmid construction
In an attempt to generate a long lasting, high efficacy peptidergic agonist of biological GLP-1, we constructed a plasmid encoding a fusion protein consisting of the human active GLP-1 (7-37) and mouse IgG 1 -Fc using overlap PCR (Figure 1 ). The IgG 1 -Fc region contains the IgG 1 constant heavy-chain (part of CH1, hinge, CH2 and CH3). An IgK secretion leader peptide sequence was inserted upstream of the GLP-1 sequence to direct the secretion of the peptide into the medium. This strategy ensures the generation of a GLP-1 fusion peptide with an active histidine residue at the N-terminus of the fusion protein after cleavage of the secretion leader sequence peptide during the process of secretion. A schematic representation of the secreted GLP-1/Fc fusion protein is shown in Figure 1b . This approach is expected to (1) circumvent the short circulating half-life of GLP-1 since IgG-Fc fusion proteins are secreted as homodimers and thus possess longer circulating half-life and higher efficacy due to higher ligand avidity [39] [40] [41] ; (2) enhance the peptide potency since most GPCRs are present as dimers in the cell membrane 34, 35 ; and (3) facilitate the purification of the peptide, which can be achieved by one-step purification using Protein G Sepharose. 42 
Mammalian expression of GLP-1-Fc fusion proteins
To assess the expression and secretion of the GLP-1/Fc fusion proteins, the plasmids were transiently transfected into COS-7 cells. At 48 h after transfection, the medium and the cells were harvested separately and the total RNA and proteins were extracted from the transfected cells. The expression of the fusion cDNAs was analyzed by RT-PCR using gene-specific primers. GLP-1-Fc fusion and IgG-Fc control transcripts were detected in the GLP-1/Fc and IgG-Fc transfected cells, respectively (Figure 2a) . No transcripts were detected in non-transfected COS-7 cells.
The lysates and media from the transfected COS-7 cells were also examined for expression of the fusion proteins by Western blotting using HRP-conjugated antimouse antibodies. As shown in Figure 2b , Fc fusion proteins were detected in both the medium and cell lysates. Coomassie Blue-staining of proteins resolved by SDS-PAGE detected a 35 kDa (Figure 3 ) and/or 70 kDa band under reducing and non-reducing conditions, respectively, indicating that the fusion proteins are synthesized and secreted from the mammalian cells and bivalent GLP-1/Fc fusion protein exists in native conditions.
The presence of the GLP-1 fusion protein in the medium from the transfected cells was further confirmed by a total GLP-1 radioimmunoassay (RIA), which allows for detection of all forms of GLP-1. COS-7 cells were transiently transfected with increasing amounts of GLP-1/Fc or IgG-Fc-only plasmids and media were collected 48 h following transfection. The medium was used in total GLP-1 RIAs. While no GLP-1 was detected in medium from non-transfected or IgG-Fc-transfected cells, GLP-1 was detected in a plasmid-dose dependent manner in the medium collected from GLP-1/Fc-transfected cells (Figure 4) .
Purification of GLP-1-Fc fusion proteins from mammalian cell culture medium
To produce larger quantities of the fusion proteins, midiscale protein purifications using Protein G Sepharose columns using 50 ml of conditioned culture media grown in 15 cm dishes from cells transfected with Total RNA (100 ng) was used in One-step RT-PCR reactions with 0.6 mM of gene-specific primers to detect transcripts. The RT-PCR products were analyzed on a 1% agarose gel and visualized using ethidium bromide (a). To detect the fusion proteins, the medium was harvested and cell lysates were prepared 48-h after transfection. IgG-Fc fusion proteins were purified using Protein G sepharose. The proteins were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was probed with anti-mouse antibody (1:5000) and visualized by ECL (b). Figure 3 Large-scale expression of IgG-Fc fusion proteins in COS-7 cells. COS-7 cells were plated in 150 mm dishes and transfected with 80 mg of DNA the following day. At 48 h after transfection, the medium was collected and fusion proteins were purified by incubating with 1 ml of Protein G Sepharose overnight. The beads were washed and the purified proteins were eluted by adding 1 ml of 0.1 M glycine (pH 2.7). The elution was repeated and the fractions were pooled. Fractions (30 ml) were analyzed by reducing or nonreducing SDS-PAGE and stained with Coomassie Blue.
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Fc-fusion vectors. The purified proteins were eluted, neutralized and desalted in a final volume of 1 ml. As shown (Figure 3 ), a two-step elution approach allows removal of most of the fusion proteins from the Sepharose column. A fraction of the samples were resolved by SDS-PAGE and visualized by Coomassie Blue staining allowing for an estimation of production and purification yield. Approximately 3 mg/ml fusion protein from 2-day static culture was purified when seeding COS-7 cells at B1.25 Â 10 5 cells/ml.
Bacterial expression of GLP-1-Fc fusion proteins
Simultaneously, we attempted to express GLP-1/Fc fusion protein in Escherichia coli cells. In order to compensate for the codon bias in E. coli. BL21 cells, Rosetta gami 2 cells were used which, in addition to allowing enhanced disulphide bond formation, harbor a plasmid for expression of seven rare tRNAs. The expressed proteins were purified using Protein G Sepharose and analyzed using SDS-PAGE and Coomassie Blue staining (data not shown). About 120 mg of GLP-1/Fc and IgG-Fc only fusion proteins could be purified from 4 liters of bacteria culture. Purified fusion proteins from mammalian and bacterial sources were further analyzed using a total GLP-1 RIA to confirm GLP-1 expression and secretion. GLP-1 peptides were detected in a dose-dependent manner in purified protein fractions. However, the expression levels of total GLP-1 were found to be lower in the bacteria than in the mammalian cells ( Figure 5 ).
In vitro characterization of GLP-1-Fc fusion proteins
Native GLP-1 stimulates insulin secretion from b-cells in a glucose-dependent manner. 43 To and fasting blood glucose weekly, and saphenous vein bleedings were collected before injection and 2 weeks and 12 weeks after the first injection for measurement of fasting insulin and glucagon levels. Expression of the GLP-1/Fc protein was evaluated by measuring plasma levels of active GLP-1 using a GLP-1 Elisa kit (Linco). As shown, 2 weeks after the first injection, the plasma GLP-1 levels were significantly elevated in mice injected with GLP-1/Fc plasmid compared to those injected with IgGFc plasmid. Curiously, GLP-1 levels were slightly increased in the control mice after 2 weeks. The plasma GLP-1 levels returned to near basal levels 16 weeks after the first injection (Figure 8a ). During the course of treatment, the bodyweight of mice in the two groups was not found to be significantly different (not shown). During the first month after injection, the fasting blood glucose levels were elevated and not significantly different between the two groups of mice (not shown). However, 3 months post-injection, the fasting blood glucose levels of the GLP-1/IgG-Fc producing mice were significantly lower than the control mice (Figure 8b , 7 vs 12 mM, Po0.001). Furthermore, while the fasting insulin levels were found to be significantly elevated in the GLP-1/Fc producing mice compared with the IgG-Fc control mice (4 vs 2.5 ng/ml Po0.05) (Figure  8c ), the fasting glucagon levels were lower in the GLP-1/ Fc mice compared to the control mice (80 vs 100 pg/ml) Po0.05) (Figure 8d ).
Discussion
This study establishes that the non-viral gene therapy of type 2 diabetes with a GLP-1/Fc construct is feasible and effective over prolonged periods of time. Strategies for enhancing the therapeutic potential of GLP-1 (as a protein drug) have been the focus of intense research in both academia and the pharmaceutical industry. 44 This includes the design and generation of modified DPP-IVresistant GLP-1 peptides with mutations in His 7,26 and Ala 8 residues. 45 However, while some of the GLP-1-derived agonists are evidently DPP-IV resistant, they Novel GLP-1 peptide M Kumar et al appear to be rapidly cleared from the plasma by other mechanisms, that is by renal clearance. A Gila monster (Heloderma suspectum) derived GLP-1R agonist, Ex-4, is DPP-IV resistant and possesses a longer half-life, which is partly attributed to the Ala-Glu substitution. Although extremely promising in animal models, daily administration of Ex-4 and/or combination therapy with oral anti-diabetic agents was required in clinical studies to normalize blood glucose levels. The need for daily injection of these peptides has motivated efforts toward development of longer-acting molecules that retain the native GLP-1 actions. It is also clear that a gene therapy approach exerting long lasting effects would have advantages over parenteral protein drug delivery.
Several strategies have been developed which focus on reducing enzymatic degradation by DPP-IV and decreasing renal clearance. In particular, in the case of NN2211, 46 acylation of GLP-1 with a fatty acid chain promotes binding of the peptide to serum albumin in vivo. This provides the peptide with the dual benefits of being DPP-IV resistant and having reduced renal filtration. 47 
CJC-1131
30 is a DPP-IV-resistant GLP-1 analog where the native L-Ala8 is substituted with a D-Ala. In addition, the GLP-1 molecule is coupled to a reactive chemical linker that can form a covalent bond with serum albumin. 30 Albugon 43 is a recombinant DPP-IV-resistant GLP-1 molecule that is generated in frame with the human serum albumin sequence. Consequently, this GLP-1R agonist has decreased clearance and prolonged half-life.
30,43
Figure 8 Effects of expression of GLP-1/Fc in db/db mice. Db/db mice were intramuscularly injected with GLP-1/Fc or IgG-Fc plasmids at 4 and 6 weeks of age. Serum was collected before injection and 2, 12 and 16 weeks after injection. Active GLP-1 levels were determined using a GLP-1 Elisa kit (a). Fasting blood glucose levels in the two groups of mice were measured 12-week after first injection (n ¼ 5-6, Po0.001) (b). Their blood insulin (c) and glucagon (d) levels were measured using RIA at 12 weeks after overnight starvation (*Po0.05; **Po0.01). The GLP-1 derived molecule described in this report is the result of the fusion of the GLP-1 and IgG1-Fc cDNA sequences (Figure 1 ). An IgG-Fc-based drug provides a numbers of advantages. 31, 48 As the IgG fusion molecules potentially form large molecular weight homodimers, they are not expected to be rapidly cleared by the kidneys, and thus have a substantially longer halflife. 31, 48 As a result, the larger GLP-1/Fc homodimeric fusion molecule is expected to have increased circulating half-life compared to native GLP-1. The GLP-1/Fc fusion protein is expected to have reduced susceptibility to degradation since such degrading enzymes have a preference for smaller peptides. 49 We have not directly measured the binding affinity of GLP-1/IgG1-Fc for the GLP-1 receptor. However, conjugation with an Fc segment and dimerization has increased the avidity of other molecules for their ligand or receptor considerably. 50 We thus hypothesize that the dimeric GLP-1 has increased ligand avidity since homodimerized GLP-1 can potentially recruit additional GLP-1Rs and amplify intracellular signaling via preformed GPCR dimers/ oligeomers. 34, 35 The cAMP and insulin secretion assays suggest that the fusion protein is able to activate GLP-1Rs in clonal INS-1 cells. The ability of the fusion protein to stimulate insulin secretion in INS-1 cells in a glucose-dependent manner further suggests that the GLP-1/Fc fusion protein retains the biological function of the native GLP-1.
The in vivo effects of the GLP-1/Fc fusion protein on lowering blood glucose levels were examined in db/db mice by an intramuscular gene transfer approach. This has the advantage of continued, long duration secretion of the fusion protein into the circulation over a period of weeks. The circulating GLP-1 fusion proteins were detectable in the db/db mice 2 weeks after intramuscular injection of GLP-1/Fc plasmids but not in the mice injected with control IgG-only plasmids. The commercial GLP-1 assay kit used in this report detects total active GLP-1, including endogenous GLP-1 and GLP-1/Fc, however, elevated serum levels of GLP-1 were only observed in mice receiving GLP-1/Fc and not the control vector encoding only the Fc portion of the molecule. Furthermore, effects attributable to GLP-1, that is, increased insulin and decreased blood glucose and glucagon, were only observed in the GLP-1/Fc group. Therefore, we conclude that the elevated GLP-1 levels depend on vector expression. Interestingly, the significant fasting blood glucose lowering effects were only observed three months after the first injection. The reduced fasting blood glucose levels in the GLP-1/Fc expressing mice were associated with increased fasting insulin levels and decreased fasting glucagon levels suggesting that the normalization of the fasting blood glucose was contributed by enhanced insulin secretion and suppressed glucagon release. It is, however, intriguing that the anti-diabetic effects of the GLP-1/Fc plasmid injection were not immediately apparent.
The db/db mice are a severe T2D animal model because of a deficiency in leptin signaling. 51, 52 Initially, the glucose levels in both the groups continued to rise perhaps as a result of progressive, unabated diabetes in the db/db mice. Normalization of glucose levels occurred at a time when GLP-1 levels were no longer significantly elevated. We hypothesize that the glucose normalization in this case may be influenced more by effects of the fusion proteins on b-cell regeneration (b-cell proliferation and neogenesis) and less by the immediate insulin sensitizing effects commonly attributed to native GLP-1. This conclusion is consistent with our and others' previous reports that GLP-1 therapy increases b-cell mass. 6, 19, 47 In addition, the severity of and the acute onset of diabetes in db/db mice could contribute to the delay in reversal of hyperglycemia. Progressive degranulation and necrosis of islets has been observed in db/db mice in addition to reduced islet insulin content. 53 Additionally, we did not see an effect of GLP-1/IgG-Fc on body weight which is seen in some cases of native GLP-1 treatment in rodent models. 54 However, anorectic effects have not been observed in several GLP-1 analogs in spite of clear insulinotrophic glucose lowering effects. 30 Treatment with the long-lasting and potent GLP-1R agonist Ex-4 improved fasting blood glucose in the db/db mice associated with enhanced b-cells mass and function. 6 However, the body weight as well as the peripheral insulin sensitivities remained unchanged. 6 These findings further support the notion that insulin resistance alone is not sufficient to trigger the onset of T2D, which occurs only when the b-cell dysfunction appears. 55, 56 The anorexic effects of GLP-1 have been linked to its action on multiple brain regions in the central nervous system. 57 The ability of the GLP-1/Fc fusion protein to penetrate the blood-brain barrier needs to be further explored.
In this study, our goal was to demonstrate that GLP-1/ Fc could indeed exert in vivo effects and impact on the manifestation of diabetes. Our results clearly demonstrate this, and establish that the effect is long lasting. As db/db mice have a severe form of type 2 diabetes, it is evident that this gene therapy approach is robust. Future studies will be aimed at assessing islet survival, growth and function in these mice, and consequent effects on glucose tolerance, insulin and C-peptide production.
The delivery of protein drugs often gives rise to the production of neutralizing antibodies in the recipient. These antibodies can diminish or abolish the activity of a peptide hormone. This can occur either because the protein is foreign (contains antigenic determinants which are not self), or because it is administered with a vehicle or by a route that promotes immunity. For example, patients receiving peptides hormones such as human insulin 58 or human growth hormone 59 can develop antibodies against these hormones. This is initiated when B-lymphocytes that have a reactive immunoglobulin receptor (B-cell receptor (BCR)) bind to the hormone. However, B-cell stimulation can be prevented by co-ligating inhibitory receptors. [60] [61] [62] [63] We postulate that B cell reactivity to GLP-1 will be prevented or diminished when this peptide is fused to an Fc segment, through binding of this Fc segment to the FcgRIIB receptor. This is consistent with the tolerogenic effects of IgG carrier proteins, as demonstrated extensively in many studies. 64 In addition, the IgG fusion approach has the advantage of a simple one-step procedure for the production of a GLP-1 fusion peptide on a laboratory scale. GLP-1 RIAs showed that the production efficiency is lower in a bacterial expression system than a mammalian expression system. This could be attributed to misfolded proteins in E. coli compared to COS-7 cells, although the use of R. gami bacterial cells was intended to enhance properly folded and functional proteins, which is achieved by increasing the formation of disulfide bonds in the E. coli cytoplasm 65 and providing rare codon tRNAs compensating for insufficient levels in the E. coli system. 66 Further optimization of culture conditions and/or extraction techniques needs to be carried out to improve the efficiency of production.
To fully characterize and compare the biological properties of GLP-1 fusion proteins, we developed vectors expressing IgG-Fc fusion of Ex-4, Ex-4 (9-39) and full-length GLP-1 (1-37). Expression and characterization of these GLP-1 and GLP-1 related fusion proteins are in progress in our laboratory and the precise mechanism behind the in vivo effects of GLP-1/IgG-Fc on blood glucose, insulin and glucagon levels are being investigated.
In summary, we have developed a method for production of GLP-1 and GLP-1 related peptides fused to IgG-Fc in order to achieve long-acting functionality and high potency. It is notable that positive in vivo effects were apparent 3 months after the treatment. Our in vitro experiments suggest that the GLP-1 fusion peptide is capable of activating GLP-1R and stimulating insulin secretion from islet b-cells in a glucose-dependent manner. In vivo gene therapy experiments using db/db mice showed that GLP-1-IgG-Fc normalized fasting blood glucose levels were associated with enhanced insulin secretion and reduced glucagon release. Indeed, this may be the first gene therapy approach to diabetes that would be readily applicable in humans. While the pharmacokinetic and pharmacodynamic profile of GLP-1 fusion proteins will be further examined in detail, this approach provides a new working model for the treatment of type 2 diabetes.
